Formulation Development of Protein Dosage Forms
`
`115
`
`Ahlnek, C., and Zografi, G., 1990, The molecular basis of moisture effects on the
`physical and chemical stability of drug in the solid state, Int J. Pharm., 62:87-95.
`Akers, M. J., 1982, Antioxidants in pharmaceutical products, J. Parenteral Sci.
`Technol. 36:222-228.
`Akers, M. J., Boand, A., and Binkley, D., 1984, Preformulation method for
`parenteral preservative efficacy evaluation, J. Pharm. Sci. 73:903-907.
`Allwood, M. C., 1982, The effectiveness of preservatives in insulin injections,
`Pharm. J. 229:340-344.
`Andya, J., Wu, S., Hsu, c., and Shire, S. J., 1996, The effect of sugars and buffer
`excipients on the stabilization of a lyophilized formulation of an anti-IgE
`humanized monoclonal antibody, Pharm. Res. 13:S-78.
`Anik, S. T., and Hwang, J. Y., 1983, Adsorption ofD-Nal(2)6LHRH, a decapeptide,
`onto glass and other surfaces, Int. J. Pharm. 16:181-190.
`Arakawa, T., and Timasheff, S. N., 1982, Preferential interaction of protein with
`salts in concentrated solution, Biochemistry 21, 6545-6552.
`Arakawa, T., and Timasheff, S. N., 1984, Mechanism of protein salting in and salting
`out by divalent cation salts: Balance between hydration and salt binding,
`Biochemistry 23: 5913-5923.
`Arakawa, T., and Timasheff, S. N., 1985, Mechanism of polyethylene glycol
`interactions with proteins, Biochemistry 24:6756-6762.
`Arakawa, T, Carpenter, J. F., Kita, Y. A., and J Crowe, J. H., 1990, The basis for
`toxicity of certain cryoprotectants: A hypothesis, Cryobiology 27:401-415.
`Arakawa, T., Kita, Y., and Carpenter, J. F., 1991, Protein-solvent interactions in
`pharmaceutical formulations, Pharm. Res. 8:285-291.
`Arakawa, T., Prestrelski, S. J., Kenney, W. c., and Carpenter, J. F., 1993, Factors
`affecting short-term and long-term stabilities of proteins, Adv. Drug Deliv. Rev.
`10:1-29.
`Badawy, S. I. F., Ghorab, M. M., and Adeyeye, C. M., 1995, Study of the complexation
`between danazol and hydrophilic cyclodextrin derivatives, Pharm. Res., 12:S204.
`Baker, R. W. (ed.), 1980, Controlled Release of Bioactive Materials, Academic Press,
`New York.
`Bam, N. B., Cleland, J. L., Yang, J., Manning, M. c., Carpenter, J. F., Kelley, R. F.,
`and Randolph, T. W., 1998, Tween protects recombinant human growth
`hormone against agitation-induced damage via hydrophobic interactions,
`J. Pharm. Sci. 87:1554-1559.
`Bam, N. B., Randolph, T. W., and Cleland, J. L., 1995, Stability of protein
`formulations: Investigation of surfactant effects by a novel EPR spectroscopic
`technique, Pharm. Res. 12:2-11.
`Becker, G. W., Tackitt, P. M., Bromer, W. W., Lefeber, D. S., and Riggin, R. M.,
`1987, Isolation and characterization of a sulfoxide and a desamido derivative of
`a dimeric form of biosynthetic human growth hormone, Biotechnol. Appl.
`Biochem. 9:478-487.
`Bell, L. N., Hageman, M. J., and Muroaka, L. M., 1995, Thermally induced
`denaturation of lyophilized bovine somatotropin and lysozyme as impacted by
`moisture and excipients, J. Pharm. Sci. 84:707-711.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 71 of 144
`
`

`

`116
`
`Michael J. Akers et at.
`
`Birnbaum, D. T., Ki1comons, M. A., DeFelippis, M. R., and Beals, J. M., 1997,
`Assembly and dissociation of human insulin and Lys pro-insulin hexamers:
`A comparison study, Pharm. Res. 14:25-36.
`Boddapati, S., Butler, L. D., 1m, S., and DeLuca, P. P., 1980, Identification of
`subvisible crystals of barium sulfate in parenteral solutions, J. Pharm. Sci.
`69:608-611.
`Boyett, J. B., and Avis, K. E., 1976, Extraction rates of marker compounds from
`rubber closures for parenteral use. II. Mechanism of extraction and evaluation
`of select extraction parameters, Bull. Parenteral Drug Assoc. 30:169-177.
`Brange, J., 1987, Galenics of Insulin, Springer-Verlag, New York.
`Brange, J., 1992, Chemical stability of insulin. 3. Influence of excipients, formulation,
`and pH, Acta Pharm. Nord. 4:149-158.
`Brange, J., and Langkjaer, L., 1993, Insulin structure and stability, in: Stability and
`Characterization of Protein and Peptide Drugs: Case Histories (Y. J. Wang and
`R. Pearlman, eds.), Plenum Press, New York, pp. 315-350.
`Brange, J., Langkjaer, L, Havelund, S., and Volund, A., 1992a, Chemical stability of
`insulin. 1. Hydrolytic degradation during storage of pharmaceutical prepara(cid:173)
`tions, Pharm. Res. 9:715-726.
`Brange, J., Havelund, S., and Hougaard, P., 1992b, Chemical stability of insulin. 2.
`Formation of higher molecular weight transformation products during storage
`of pharmaceutical preparations, Pharm. Res. 9:727-734.
`Brennan, J. R., Gebhart, S. S. P., and Ba1ckard, W. G., 1985, Pump-induced insulin
`aggregation, Diabetes 34:353-359.
`Brewster, M. E., Simpkins, J. W., Hora, M. S., Stern, W. C., and Bodor, N., 1989,
`The potential use of cyclodextrins in parenteral formulations, J. Parenteral Sci.
`Technol.43:231-240.
`Brewster, M. E., Hora, M. S., Simpkins, J. W., and Bodor, N., 1991, Use of 2-
`hydroxypropyl-fJ-cyclodextrin as a solubilizing and stabilizing excipient for
`protein drugs, Pharm. Res. 8:792-795.
`Brose, D. J. and Waibel, P., 1996, Adsorption of proteins in commercial
`microfiltration capsule, Pharm. Technol. 20:48-52.
`Brot, N., and Weissbach, H., 1982, The biochemistry of methionine residues in
`proteins, Trends Biochem. Sci. 7:137-139.
`Brown, M. and Leeson, L. J., 1969, Protection of oxygen-sensitive pharmaceuticals,
`J. Pharm. Sci. 58:242-245.
`Capasso, S., Mazzarella, L., and Zagari, A., 1991, Deamidation via cyclic imide of
`asparaginyl peptides: Dependence on salts, buffers, and organic solvents,
`Peptide Res. 4:234-238.
`Carpenter, J. F., and Crowe, J. H., 1988, The mechanism of cryoprotection of
`proteins by solutes, Cryobiology 25:244-255.
`Carpenter, J. F., and Crowe, J. H., 1989, An infrared spectroscopic study of the
`interactions of carbohydrates with dried protein, Biochemistry 28:3916-3922.
`Carpenter, J. F., Prestrelski, S. J., and Arakawa, T., 1993, Separation of freezing and
`drying-induced denaturation of lyophilized proteins using stress-specific
`stabilization, Arch Biochem Biophys. 303:456-464.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 72 of 144
`
`

`

`Formulation Development of Protein Dosage Forms
`
`117
`
`Chang, B. S., Kendrick, B. S., and Carpenter, J. F., 1996, Surface-induced
`denaturation of proteins during freezing and its inhibition by surfactants,
`J. Pharm. Sci. 85:1325-1330.
`Chawla, A. S., Hinberg, I., Blais, P., and Johnson, D., 1985, Aggregation of
`insulin, containing surfactants, in contact with different materials, Diabetes 34:
`420-424.
`Chrai, S., Heffernan, G., and Myers, T., 1994, Glass vial container--closure integrity
`testing-an overview, Pharm. Technol. 18:162-175.
`Christensen, P., Johansson, A., and Nielsen, V., 1978, Quantitation of protein
`adsorbance to glass and plastics: Investigation of a new tube with low
`adherence, J. Immunol. Meth. 23:23-28.
`Clarke, S., Stephenson, R. c., and Lowenson, J. D., 1992, Lability of asparagine and
`aspartic acid residues in proteins and peptides. Spontaneous deamidation and
`isomerization reactions, In: Stability of Protein Pharmaceuticals, Part A:
`Chemical and Physical Pathways of Protein Degradation (T. J. Ahern and
`M. C. Manning, eds.), Plenum Press, New York, pp. 2-29.
`Cleland, J. L., Powell, M. F., and Shire, S. J., 1993, The development of stable
`protein formulations: A close look at protein aggregation, deamindation and
`oxidation, Crit. Rev. Ther. Drug Carrier Syst. 10:307-377.
`Costantino, H. R., Carrasquillo, K. G., Cordero, R. A., Mumenthaler, M.,
`Hsu, C. c., and Griebenow, K., 1998, Effect of excipients on the stability and
`structure of lyophilized recombinant human growth hormone, J. Pharm. Sci.
`87:1412-1420.
`Cradock, J. c., Kleinman, L. M., and Davignon, J. P., 1977, Intrathecal injections(cid:173)
`A review of pharmaceutical factors, Bull. Parenteral Drug Assoc. 31: 237-247.
`Currie, B. L., and Groves, M. J., 1992, Protein stability and degradation mechanisms,
`in: Pharmaceutical Biotechnology (M. E. Klegerman and M. J. Groves, eds.),
`Interpharm Press, Englewood, CO, pp. 213-216.
`Dahlquist, F. W., Long, J. W., and Bigbee, W. L., 1976, Role of calcium in thermal
`stability of thermolysin, Biochemistry, 15: 11 03-1111.
`Danielson, J. W., Oxborrow, G. S., and Placencia, A. M., 1984, Quantitative
`determination of chemicals leached from rubber stoppers into parenteral
`solutions, J. Parenteral Sci. Technol. 38:90--93.
`Davis, S. S., Illum, L., and Tomlinson, E., 1986, Delivery Systems for Peptide Drugs,
`Plenum Press, New York.
`Deadman, M. L., Farmer, T. H., and Morris, C. J. O. R., 1961, Studies on pituitary
`adrenocorticotrophin, Biochem. J. 78:348-352.
`DeLuca, P. P. and Knapp, J. Z., 1993, Particulate matter, in: Pharmaceutical Dosage
`Forms, Parenteral Medications, Volume 3, 2nd ed. (K. E. Avis, H. A. Lieberman,
`and L. Lachman, eds.), Marcel Dekker, New York, pp. 117-230.
`Dixon, H. B. F., 1956, The melanophore stimulating activity of corticotrophin,
`Biochim. Biophys. Acta. 19:392.
`Dong, D. E., Andrade, J. D., and Coleman, D. L., 1987, Adsorption of low density
`lipoproteins onto selected biomedical polymers, J. Biomed. Mater. Res. 21,
`683-700.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 73 of 144
`
`

`

`118
`
`Michael J. Akers et al.
`
`Dubost, D. c., Kaufman, M. J., Zimmerman, J. A., Bogusky, M. J.,
`Coddington, A. B., and Pitzenberger, S. M., 1996, Characterization of a
`solid state reaction product from a lyophilized formulation of a cyclic
`heptapeptide. A novel example of an excipient-induced oxidation, Pharm.
`Res. 13:1811-1814.
`Federal Register, 1994, Stability testing of new drugs and products, Fed. Reg.
`59(183):48754-48759.
`Federal Register, 1997, Proposed Rule 21CFR Part 589, Substances prohibited from
`use in animal food or feed, animal proteins prohibited in ruminant feed, Fed.
`Reg. 62(2):551-583.
`Fischer, J., 1995, Bovine spongiform encephalopathy, Deutsche Apotheker Zeitung,
`135:35-47.
`Fish, W. W., Danielsson, A., Nordling, L., Miller, S. H., Lam, C. F. and Bjork I.,
`1985, Denaturation behavior of antithrombin in guanidinium chloride:
`Irreversibility of unfolding caused by aggregation, Biochemistry 24:1510.
`Franks, F., 1990, Freeze drying: From empiricism to predictability, Cryo-Lett,
`11:93.
`Franks, F., 1994, Long term stabilization of biologicals, Biotech. 12:253-256.
`Franks, F., Hatley, R. H. M., and Friedman, H. L., 1988, The thermodynamics of
`protein stability: Cold destabilization as a general phenomenon, Biophys. Chem.
`31:307-315.
`Franks, F., Hatley, R. H. M., and Mathias, S. F. 1991, Materials science and the
`production of shelf-stable biologicals, BioPharm 4:38-42.
`Fransson, J., and Hagman, A., 1996, Oxidation of human insulin-like growth factor
`I in formulation studies. 2. Effects of oxygen, visible light, and phosphate on
`methionine oxidation in aqueous solution and evaluation of possible mechan(cid:173)
`isms, Pharm Res. 13:1476-1481.
`Friedman, M., and Masters, P. M., 1982, Kinetics of racemization of amino acid
`residues in casein, J. Food Sci. 47:760-765.
`Galat, A., Creighton, T., Lord, R. C., and Blout, E. R., 1981, Circular dichroism,
`Raman spectroscopy, and gel filtration of trapped folding intermediates of
`ribonuclease, Biochemistry 20:594-60 I.
`Geiger, T., and Clarke, S., 1987, Deamidation, isomerization, and racemization of
`asparginyl and aspartyl residues in pep tides, J. Bioi. Chem. 262:785-794.
`Gekko, K., and Timasheff, S. N., 1981, Mechanism of protein stabilization by
`glycerol: Preferred hydration in glycerol-water mixtures, Biochemistry 20:
`4667-4676.
`Glatz, C. E., 1992, Modeling of aggregation-precipitation phenomena, in: Stability
`of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein
`Degradation, (T.J. Ahern, and M. C. Manning, eds.), Plenum Press, New York,
`pp. l35-166.
`Gorecka, B. A., Sanzgiri, Y. D., Bindra, D. S., and Stella, V. J., 1995, Effect ofSBE4-f3-
`CD, a sulfobutylether f3-cyclodextrin, on the stability and solubility of 0 6_
`in aqueous solutions, Int. J. Pharm. 125:
`benzyguanine (NSC-637037)
`55-61.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 74 of 144
`
`

`

`Formulation Development of Protein Dosage Forms
`
`119
`
`Gu, L. c., Erdos, E. A., Chiang, H. -S., Calderwood, T., Tsai, K., Visor, G. c.,
`Duffy, J., Hsu, W. -C., and Foster, L. C., 1991, Stability of inter leu kin Ib (IL(cid:173)
`l b) in aqueous solution: Analytical methods, kinetics, products, and solution
`formulation implications, Pharm. Res. 8:485-490.
`Guazzo, D., 1994, Package integrity testing, in: Parenteral Quality Control: Sterility,
`Pyrogen, Particulate Matter and Package Integrity Testing (M. J. Akers, ed.),
`Marcel Dekker, New York, pp. 258-262.
`Haber, E., and Anfinsen, C. B., 1962, Side-chain interactions governing the pairing
`of half-cystine residues in ribnucIease, J. Bioi. Chern. 237, 1839.
`Hageman, M., 1988, The role of moisture in protein stability, Drug Dev. Ind. Pharm.
`14, 2047-2070.
`Haley, E. E., Corcoran, B. J., Dorer, R. D., and Buchanan, D. L., 1966, j3-Aspartyl
`peptides in enzymatic hydrolysates of proteins, Biochemistry 5:3229-3235.
`Hanson, M. A., and Rouan, S. K. E., 1992, Introduction to formulation of protein
`pharmaceuticals, in: Stability of Protein Pharmaceuticals, Part B: In Vivo
`Pathways of Degradation and Strategies for Protein Stabilization (T. J. Ahem
`and M. C. Manning, eds.), Plenum Press, New York, pp. 209-233.
`Harwood, R. J., Portnoff, J. B., and Sunbery, E. W. 1993, The processing of
`small volume parenterals and related sterile products, in: Pharmaceutical
`Dosage Forms: Parenteral Medications, Vol. 2, 2nd ed. K. E. Avis, H. A.
`Lieberman, and L. Lachaman, eds.), Marcel Dekker, New York, pp. 36--37.
`Hawker, R. J. and Hawker, L. M., 1975, Protein losses during sterilizing by
`filtration, Lab. Practice 24:805-807.
`Her, L. M. and Nail, S. L., 1994, Measurement of glass transition temperatures of
`freeze-concentrated solutes by differential scanning calorimetry, Pharm. Res.
`11:54--59.
`Hillery, A. M., Lloyd, A. W., and Swarbrick, J., eds., 2001, Drug Delivery and
`Targeting for Pharmacists and Pharmaceutical Scientists, Taylor and Francis,
`London.
`Hirsch, J. I., Fratkin, M. J., Wood, J. H., and Thomas, R. B., 1977, Clinical
`significance of insulin adsorption by polyvinyIchloride infusion systems, Am. J.
`Hosp. Pharm. 34:583-588.
`Hirsch, J. I., Wood, J. H., and Thomas, R. B., 1981, Insulin adsorption to polyolefin
`infusion bottles and polyvinyIchloride administration sets, Am. J. Hosp. Pharm.
`38:995-997.
`Hoffman, A. S., 1974, Principles governing biomolecule interactions at foreign
`interfaces, J. Biomed. Mater. Res. Symp. 5(Part 1):77-83.
`Hora, M. S., Rana, R. K., Wilcox, C. L, Katre, N. V., Hirtzer, P., Wolfe, S., and
`Thomson, J. W., 1991, Development of a lyophilized formulation of interleukin-2,
`Dev. Bioi. Stand. 74:295-303.
`Hora, M. S., Rana, R. K., and Smith, F. W., 1992, Lyophilized formulations of
`recombinant tumor necrosis factor, Pharm. Res. 9:33-36.
`Hsu, C. c., Pearlman, R., and Curley, J. c., 1988, Some factors causing protein
`denaturation and aggregate formation in pharmaceutical processing, Pharm.
`Res. Suppl. 5:S34.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 75 of 144
`
`

`

`120
`
`Michael J. Akers et al.
`
`Hsu, C. C., Ward, C. A., Pearlman, R., Nguyen, H. M., Yeung, D. A., and Curley, J. G.,
`1991, Determining the optimum residual moisture in lyophilized protein
`pharmaceuticals, Dev. Bioi. Stand. 74:255-271.
`International Conference on Harmonization, 1995, Quality of Biotechnology
`Products: Stability Testing of Biotechnological/Biological Products, Annex to
`the Tripartite ICH Guideline for the Stability Testing of New Drug Substances
`and Products, ICH, Geneva.
`Iwamoto, G. K., Van Wagenen, R. A., and Andrade, J. D., 1982, Insulin
`adsorption: Intrinsic tyrosine interfacial fluorescence, J. Colloid Interface Sci.
`86:581-585.
`Izutsu, K., Yoshioka, S., and Terao, T., 1993a, Stabilization of fJ-galactosidase by
`amphiphilic additives during freeze drying, Int. J. Pharm. 90:187-194.
`Izutsu, K., Yoshioka, S., and Terao, T., 1993b, Decreased protein-stabilizing effects
`of cryoprotectants due to crystallization, Pharm. Res. 10:1232-1237.
`Izutsu, K., Yoshioka, S., and Terao, T., 1994a, Effect of mannitol crystallinity on the
`stabilization of enzymes during freeze drying, Chem Pharm. Bull. 42:5-8.
`Izutsu, K., Yoshioka, S., and Kojima, S., 1994b, Physical stability and protein
`stability of freeze dried cakes during storage at elevated temperatures, Pharm.
`Res. 11:995-999.
`James, D. E., Jenkins, A. B., Kraegan, E. W., and Chisholm, D. J., 1981, Insulin
`precipitation in artificial infusion devices, Diabetologia 21:554-557.
`Jang, J. W., Kitamura, S., and Guillory, J. K., 1995, The effect of excipients on glass
`transition temperatures for FK906 in the frozen and lyophilized states, PDA J.
`Pharm. Sci. Technol.49:166-174.
`Jarvinen, K., Jarvinen, T., Thompson, D.O., and Stella, V. J., 1994, The effect of a
`modified fJ-cyclodextrin, SBE4-f3-CD on the aqueous stability and ocular
`absorption of pilocarpine, Curro Eye Res. 13:897-905.
`Johnson, M. D., Hoesterey, B. L., and Anderson, B. D., 1994, Solubilization of a
`tripeptide HIV protease inhibitor using a combination of ionization and
`complexation with chemically modified cyclodextrins, J. Pharm. Sci. 83:
`1142-1146.
`Johnston, T. P., 1996, Adsorption of recombinant human granulocyte colony
`stimulating factor (rGH-CSF) to polyvinyl chloride, polypropylene, and glass:
`Effect of solvent additives, PDA J. Pharm. Sci. Techno!. 50:238-245.
`Kakimoto, F., Asakawa, N., Ishibashi, Y., and Miyake, Y., 1985, Prevention of
`adsorption of peptide hormones, Eisai Co. Ltd, Japan Patent JP61221125-
`A2861001.
`Katakam, M., Bell, L. N., and Banga, A. K., 1995, Effect of surfactants on the
`physical stability of recombinant human growth hormone, J. Pharm. Sci.
`84:713-716.
`Kerwin, B. A., Akers, M. J., Apostol, I., Moore-Einsel, c., Etter, J. E., Hess, E.,
`Lippincott, J., Levine, J., Mathews, A. J., Revilla-Sharp, P., Schubert, R., and
`Looker, D. L., 1999, Acute and long-term stability studies of deoxy hemoglobin
`and characterization of ascorbate-induced modifications, J. Pharm. Sci. 88:79-
`88.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 76 of 144
`
`

`

`Formulation Development of Protein Dosage Forms
`
`121
`
`Kim, Y., Rose, C. A., Liu, Y., Ozaki, Y., Datta, G., and Ut, A. T., 1994, RT-IR and
`near-infared FT-raman studies of the secondary structure of insulinotropin in
`the solid state: IX-Helix to fJ-sheet conversion induced by phenol and/or high
`shear force, J. Pharm. Sci. 83:1175-1180.
`Kirsch, L. E., Riggin, R. M., Gearhart, D. A., Lefeber, D. S., and Lytle, D. L., 1993,
`In-process protein degradation by exposure to trace amounts of sanitizing
`agents, J. Parenteral Sci. Technol.47:155-160.
`Kirsch, L. E., Nguyen, L., Moeckly, C. S., 1997a, Pharmaceutical container/closure
`integrity I: Mass spectrometry-based helium leak rate detection for rubber(cid:173)
`stoppered glass vials, PDA J. Pharm, Sci. Tech. 51:187-194.
`Kirsch, L. E., Nguyen, L., Moeckly, C. S., Gerth, R., 1997b, Pharmaceutical
`container/closure integrity II: The relationship between microbial ingress and
`helium leak rates in rubber-stoppered glass vials, PDA J. Pharm, Sci. Tech.
`51:195-202.
`Kirsch, L. E., Nguyen, L., Gerth, R., 1997c, Pharmaceutical container/closure
`integrity III: Validation of the helium leak rate for rigid pharmaceutical
`containers, PDA J. Pharm. Sci. Tech. 51:203-207.
`Knepp, V. M., Whatley, J. L., Muchnik, A., and Calderwood, T. S., 1996,
`Identification of antioxidants for prevention of peroxide-mediated oxidation of
`recombinant human ciliary neurotrophic factor and recombinant human nerve
`growth factor, PDA J. Pharm. Sci. Techno!. 50:163-171.
`Kraegen, E. W., Lazarus, L., Meier, H., Campbell, L., and Chia, Y. 0., 1975,
`Carrier solutions for low level intravenous insulin infusion, Br. Med. J. 1975:
`464-466.
`Kreilgard, L., Frokjaer, S., Flink, J. M., Randolph, T. W., and Carpenter, J. F.,
`1996, The effects of sugars, polymers, and surfactants on conformational
`stability of a hydrophobic protein during freeze-drying, Pharm. Res. 13:S-79.
`Lam, X. M., Costantino, H. R., Overcashier, D. E., Nguyen, T. H., and Hsu, C. c.,
`1996, Replacing succinate with glycolate buffer improves the stability of
`lyophilized interferon-gamma, Int. J. Pharm. 142:85-95.
`Lam, X. M., Patapoff, T. W., and Nguyen, T. H., 1997, The effect of benzyl alcohol
`on recombinant human interferon-y, Pharm. Res. 14:725-729.
`Lang, L. A., 1996, A review of latex hypersensitivity, Toxic Substances Mechanisms
`15:1-11.
`Lee, H. S., Osuga, D. T., Nashaf, A. S., Ahmed, A. I., Whitaker, J. R., and Feeney,
`R. E., 1977, Effects of alkali on glycoproteins: fJ-Elimination and nucleophilic
`addition reactions of substitued threonyl residues of antifreeze glycoprotein,
`J. Agr. Food Chem. 25:1153-1158.
`Lee, J. C. and Lee, L. L. Y., 1987, Thermal stability of proteins in the presence of
`polyethylene glycols, Biochemistry 26:7813-7819.
`Lee, V. H. L. (ed.), 1997, Peptide and Protein Drug Delivery, 2nd ed., Marcel Dekker,
`New York.
`Lenk, J. R., Ratner, B. D., Gendreau, R. M., and Chittur, K. K., 1989, IR spectral
`changes of bovine serum albumin upon surface adsorption, J. Biomed. Mater.
`Res. 23:549-569.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 77 of 144
`
`

`

`122
`
`Michael J. Akers et al.
`
`Li, S., Schoneich, c., Wilson, G. S., and Borchardt, R. T, 1993, Chemical pathways
`of peptide degradation. V. Ascorbic acid promotes rather than inhibits the
`oxidation of methionine to methionine sulfoxide in small model peptides,
`Pharm. Res. 10:1572-1579.
`Liebe, D. c., 1995, Pharmaceutical packaging, in: Encyclopedia of Pharmaceutical
`Technology, Vol. 12 (J. Swarbrick and J. C. Boylan, eds.), Marcel Dekker, New
`York, pp. 16-28.
`Liu, W. R., Langer, R., and Klibanov, A. M., 1991, Moisture-induced aggregation
`of lyophilized proteins in the solid state, Biotechnol. Bioeng. 37: 177-182.
`Lougheed, W. D., Albisser, A. M., Martindale, H. M., Chow, J. c., and Clement, J. R.,
`1983, Physical stability of insulin formulations, Diabetes 32:424-432.
`Maa, Y. F., and Hsu, C. c., 1996, Int. J. Pharm. 140:155-168.
`MacCracken, J., 1996, Latex allergy in diabetic patients: A call for latex-free insulin
`tops, Diabetes Care 19:184.
`Manning, M. C., Patel, K., and Borchardt, R. T., 1991, Stability of protein
`pharmaceuticals, Pharm. Res. 6:903-918.
`Massey, E. H. and Sheliga, T. A., 1988, Human insulin (HI) isophane solution
`(NPH) with improved physical stability, Pharm. Res. 5:S34.
`Milano, E. A., Waraszkiewicz, S. M., and Dirubio, R., 1982, Extraction of soluble
`aluminum from chlorobutyl rubber closures, J. Parenteral Sci. Technol.36:116-
`120.
`Mitraki, A., and King, J., 1989, Protein folding intermediates and inclusion body
`formation, Biotechnology. 7:690-696.
`Mitrano, F. P. and Newton, D. W., 1982, Factors affecting insulin adherence to Type
`I glass bottles, Am. J. Hosp. Pharm. 39:1491-1495.
`Mizutani, T., 1981, Estimation of protein and drug adsorption onto silicone--coated
`glass surfaces, J. Pharm. Sci. 70:493-496.
`Mizutani, T., and Mizutani, A., 1975, Prevention of adsorption of protein on
`controlled-pore glass with amino acid buffer, J. Chromatogr. 111:214-216.
`Mizutani, T., and Mizutani, A., 1978, Adsorption of a protein on glass surfaces in
`detergent solutions, J. Non-cryst. Solids 27:437-439.
`Morley, J. S., Tracey, H. J., and Gregory, R. A., 1965, Structure-function relationships
`in the active C-terminal tetrapeptide sequence of gastrin, Nature 207:1356-1359.
`Morton, D. K., Lordi, N. G., Troutman, L. H., and Ambriosio, T. J., 1989, Quantitative
`and mechanistic measurements of container/closure integrity. Bubble, liquid, and
`microbia11eakage tests, J. Parenteral Sci. Technol.43: 104-108.
`Murase, M., and Franks, F., 1989, Salt precipitation during the freeze concentration
`of phosphate buffer solution, Biophys. Chem. 34:293-300.
`Nash, R. A., 1994, Cyclodextrins, in: Handbook of Pharmaceutical Excipients, 2nd
`ed. CA. Wade and P. J. Weller, eds.), American Pharmaceutical Association,
`Washington, DC, pp. 145-148.
`Niebergall, P. J., 1990, Ionic solutions and electrolytic equilibria, in: Remington's
`Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Philadelphia, PA, pp.
`213-230.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 78 of 144
`
`

`

`Formulation Development of Protein Dosage Forms
`
`123
`
`Norde, W., 1995, Adsorption of proteins at solid-liquid interfaces, Cells Materials
`5:97-112.
`Ogino, J., Noguchi, K., and Terato, K., 1979, Adsorption of secretin on glass
`surfaces, Chem. Pharm. Bull. 27:3160-3163.
`Okimoto, K., Rajewski, R. A., Jona, J. A., and Stella, V. J., 1995, The interaction of
`charged and uncharged drugs with a neutral (HP-fJ-CD) and anionically
`charged (SBE7-fJ-CD) cyclodextrin, Pharm. Res. 12:S205.
`Oliyai, c., Patel, J. P., Carr, L., and Borchardt, R. T., 1994, Chemical pathways of
`peptide degradation. VII. Solid state chemical instability of an aspartyl residue
`in a model hexapeptide, Pharm. Res. 11,901-908.
`Orii, Y., and Morita, M., 1977, Measurement of the pH of frozen buffer solutions by
`using pH indicators, J. Biochem. 81:163-168.
`Oshima, G., 1989, Solid surface-catalyzed inactivation of bovine alpha-chymotrypsin
`in dilute solution, Int. J. BioI. Macromol. 11:43-48.
`Pace, C. N. and Grimsley, G. R., 1988, Ribonuclease Tl is stabilized by cation and
`anion binding, Biochemistry 27:8311-8315.
`Pantoliano, M. W., Whitlow, M., Wood, J. F., Rollence, M. L., Finzel, B. c.,
`Gilliand, G. L., Poulos, G., and Bryant, P. N., 1988, The engineering of binding
`affinity at metal ion binding sites for the stabilization of proteins: Subtilisin as a
`test case, Biochemistry 27:8311-8316.
`Parenteral Drug Association, 1980, Extractables from Elastomeric Closures:
`Analytical Procedures for Function Group, Characterization, and Identifica(cid:173)
`tion, Methods Bulletin No.1, PDA, Bethesda, MD.
`Parenteral Drug Association, 1982, Elastomeric Closures: Evaluation of Significant
`Performance and Identity Characteristics, Technical Methods Bulletin 2, PDA,
`Bethesda, MD.
`Parenteral Drug Association, 1986, Glass: Isolation and identification of extractables
`from USP grade glass, J. Parenteral Sci. Technol. 40, S3-S11.
`Patel, J. P., 1990, Urokinase: Stability studies in solution and lyophilized
`formulations, Drug Dev. Ind. Pharm. 16:2613-2626.
`Pearlman, R., and Wang, Y. J., 1996, Formulation, Characterization, and Stability of
`Protein Drugs, Plenum Press, New York.
`Petty, c., Cunningham, N., and Major, M. c., 1974, Insulin adsorption by glass
`infusion bottles, polyvinylchloride infusion containers, and intravenous tubing,
`Anesthesiology 40:400-404.
`Pharmacopeial Forum, 1996, The United States Pharmacopeial Convention, Inc. No.
`31, Sept.-Oct.
`Pikal, M. J., 1990, Freeze drying of proteins. II. Formulation selection, BioPharm.
`3:26-30.
`Pikal, M. J., 2002, Freeze drying of proteins, in: Peptide and Protein Delivery, 2nd ed.
`(V. H. L. Lee, ed.), Marcel Dekker, New York (in press).
`Pikal, M. J., Dellerman, K. M., Roy, M. L., and Riggin, R. M., 1991a, The effects of
`formulation variables on the stability of freeze dried human growth hormone,
`Pharm. Res. 8:427-436.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 79 of 144
`
`

`

`124
`
`Michael 1. Akers et al.
`
`Pikal, M. 1., Dellerman, K. M., and Roy, M. L., 1991b, Formulation and stability of
`freeze dried proteins: Effects of moisture and oxygen on the stability of freeze
`dried formulations of human growth hormone, Dev. BioI. Stand. 74:21-37.
`Privalov, P. L., 1990, Cold denaturation of proteins, Crit. Rev. Biochem. Mol. BioI.
`25:281-305.
`Rajewski, R. A. and Stella, V. 1., 1996, Pharmaceutical applications of cyclodextrins.
`2. In vivo drug delivery, J. Pharm. Sci. 85:1142-1169.
`Riffkin, c., 1968, Panel discussion: Siliconization of parenteral packaging
`components, Bull. Parenteral Drug Assoc. 22:66-75.
`Riniker, V. B., Neher, R., Maier, R., Kahnt, F. W., Byfield, P. G. H.,Gundmunds(cid:173)
`son, T. V., Galante, L., and MacIntyre, I., 1968, Menschliches calcitonin I:
`Isolierung und charakterisierung, Helv. Chim. Acta 51: 1738-1743.
`Robinson, A. B., and Rudd, C. 1., 1974, Deamidation of glutaminyl and asparaginyl
`residues in peptides and proteins, in: (B. L. Horecker and E. R. Stadtman, eds.),
`Current Topics in Cellular Regulation, Vol. 8, Academic Press, New York, pp.
`247-295.
`Roe, 1. A., Butler, A., Schaller, D. M., and Valentine, 1. S., 1988, Differential
`scanning calorimetry of Cu, Zn-superoxide dismutase, the apoprotein, and its
`Zn-substituted derivatives, Biochemistry 27:950-995.
`Ryan, W., Collier, P., Satyagal, V., Sachdev, R., and Sumodojo, F., 1995,
`Characterization of a cryogenic pelletizer for preserving delicate biologicals,
`BioPharm 8:32-38.
`Ryle, A. P., and Sanger, F., 1955, Disulfide interchange reactions, Biochem J.
`60:535-539.
`Sato, S., Ebert, C. D., and Kim, S. W., 1984, Prevention of insulin self-association
`and surface adsorption, J. Pharm. Sci. 72:228-232.
`Schmidt, D. 1., and Akers, M. 1., 1997, Cryogranulation-A potential new final
`process for bulk drug substances, BioPharm 10:28-32.
`Sen, L. C., Gonzalez-Flores, E., Feeney, R. E., and Whitaker, 1. R., 1977, Reactions
`of phosphoproteins in alkaline solutions, J. Agr. Food Chem. 25:632-638.
`Senior, 1., and Radomsky, M., eds., 2000, Sustained-Release Injectable Products,
`Interpharm Press, Englewood, Co.
`Seres, D. S., 1990, Insulin adsorption to parenteral infusion systems: Case report and
`review of the literature, Nutr. Clin. Pract. 5:111-117.
`Shahrokh, Z., Eberlein, G., and Wang, Y. 1., 1994a, Probing the conformation of
`protein (bFGF) precipitates by fluorescence spectroscopy, J. Pharm. Biomed.
`Anal. 12:1035-1041.
`Shahrokh, Z., Sluzky, V., Stratton, P. R. and Eberlein, G. A., 1994b, Disulfide(cid:173)
`linked oligomerization of basic fibroblast growth factor: Effects of sulfated
`compounds, in: ACS Symposium Series on Protein Formulation and Delivery (1.
`Cleland and R. Langer, eds.), American Chemical Society Publishing, pp. 85-
`99.
`Shnek, D. R., Hostettler, D. L., Bell, M. A., Olinger, 1. M., and Frank, B. H., 1998,
`Physical stress testing of insulin suspensions and solutions, J. Pharm. Sci.
`87:1459-1465.
`
` PFIZER, INC. v. NOVO NORDISK A/S - IPR2020-01252, Ex. 1024, p. 80 of 144
`
`

`

`Formulation Development of Protein Dosage Forms
`
`125
`
`Silvestri, S., Lu, M. Y., and Johnson, H., 1993, Kinetics and mechanism of peptide
`aggregation I: Aggregation of a cholecystokinin analog, J. Pharm. Sci.
`92:689-693.
`Simkins, J. W., 1991, Solubilization of ovine growth hormone with 2-hydroxypropyl(cid:173)
`fl-cyclodextrin, J. Parenteral Sci. Technol. 45:266-269.
`Slater, J. E., 1994, Latex allergy, J. Allergy Clin. Immunol. 94:139-149.
`Smith, E. J., and Nash, R. J. (1992). Elastomeric closures for parenterals, in:
`Pharmaceutical Dosage Forms: Parenteral Medications, Vol. I, 2nd ed., (K. R.
`Avis, H. A. Lieberman, and L. Lachman, eds.), Marcel Dekker, New York,
`pp.445-512.
`Srinivasan, N., Sowdhamini, R., Ramakrishnan, c., and Balaram, P., 1990, Conforma(cid:173)
`tion of disulfide bridges in proteins, Int. J. Peptide Protein Res. 36: 197-155.
`Stratton, C. E., 1991, Cyclodextrins and biological macromolecules, BioPharm.
`4:44-49.
`Suelter, C. H., and DeLuca, P. P., 1983, How to prevent losses of protein by
`adsorption to glass and plastic, Anal. Biochem. 135:112-119.
`Szkudlarek, B. A., Garcia, G. A. and Rodriguez-Hornedo, N., 1996, The effect of
`freezing on the stability of lactate dehydrogenase in phosphate buffer solutions
`in the absence and presence of additives, Pharm. Res. 13:S85.
`Tanaka, R., Takeda, T., and Miyajima, R., 1991, Cryoprotective effect of
`saccharides on denaturation of catalase during freeze drying, Chem. Pharm.
`Bioi. 39:1091-1094.
`Tashjian, A. H., Ontjes, D. A., and Munson, P. L., 1964, Alkylation and oxidation
`of methionine in bovine parathyroid hormone: Effects on hormonal activity and
`antigenicity, Biochemistry 3:1175-1182.
`Thompson, D.O., 1997, Cyclodextrins-enabling excipients: Their present and future
`use in pharmaceuticals, Crit. Rev. Ther. Drug Carrier Syst. 14:1-104.
`Thurow, H., and Geisen, K., 1984, The stabilisation of dissolved proteins against
`denaturation at